Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 1
1964 1
1965 4
1966 3
1968 2
1969 2
1970 3
1971 3
1972 9
1973 7
1974 8
1975 9
1976 6
1977 6
1978 9
1979 10
1980 6
1981 10
1982 5
1983 6
1984 7
1985 7
1986 2
1987 10
1988 6
1989 7
1990 11
1991 15
1992 11
1993 14
1994 9
1995 5
1996 15
1997 27
1998 20
1999 30
2000 31
2001 25
2002 30
2003 33
2004 37
2005 46
2006 59
2007 32
2008 66
2009 36
2010 40
2011 51
2012 51
2013 41
2014 62
2015 49
2016 39
2017 40
2018 42
2019 55
2020 44
2021 66
2022 58
2023 56
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

1,301 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: chiu jwy. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: chiu jwy. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Free article. Clinical Trial.
Pembrolizumab (Keytruda).
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Kwok G, et al. Among authors: chiu jw. Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310. Epub 2016 Jul 11. Hum Vaccin Immunother. 2016. PMID: 27398650 Free PMC article. Review.
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS. Gutierrez M, et al. Among authors: chiu jwy. Nat Med. 2023 Jul;29(7):1718-1727. doi: 10.1038/s41591-023-02385-6. Epub 2023 Jul 10. Nat Med. 2023. PMID: 37429923 Clinical Trial.
Expert witnesses and areas of expertise.
Chiu JSP, Leung GKK. Chiu JSP, et al. Hong Kong Med J. 2022 Feb;28(1):4-5. doi: 10.12809/hkmj215125. Epub 2022 Feb 14. Hong Kong Med J. 2022. PMID: 35249889 Free article. No abstract available.
1,301 results